Insulet Corporation
PODD
$3.29 (1.13%)
1D
1W
3M
1Y
5Y
ALL
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Business Wire • 2 days ago • PODD
Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference
Zacks Investment Research • 3 days ago • PODD
4 Medical Device Stocks to Buy for Healthy Returns in 2026
Business Wire • 3 days ago • PODD
Insulet Expands OmnipodĀ® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future
Zacks Investment Research • 8 days ago • PODD
Here is Why Growth Investors Should Buy Insulet (PODD) Now
Zacks Investment Research • 10 days ago • PODD
PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.